Vanda Pharmaceuticals, Inc. (VNDA) Posts Wider than Expected Q4 Loss
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.90 --0%
Revenue Growth %: +17.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +17.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q4 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $8.2 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
- OptimizeRX (OPRX) Reiterated at Market Outperform by Citizens Before Annual Forum
- Evercore ISI Upgrades Canadian National Railway (CNI) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
